Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has transformed biological research and therapeutic development. Different Cas proteins offer unique editing capabilities and targeting requirements, directed by the guide RNA to the targeted sequences.
As a leading provider of gene editing technology and partner of the Broad Institute, GenScript offers one-stop solution of Cas protein including a broad portfolio of off-the-shelf products and customized services, with cGMP expertise and global IND track records, to provide researchers an integrated CRISPR workflow solution, accelerate clinical entry and commercialization.
Spanning across Cas9, Cas12a, MAD7, Cas13a, and next-generation Base Editors and Prime Editors - engineered for high efficiency, low off-target rates, and broad cell type compatibility. Available in both RUO and cGMP formats. Check out >>
Our custom Cas protein service delivers RUO to cGMP nucleases with industry leading speed, scalable manufacturing capacity, comprehensive assay development capability and IND regulatory support to accelerate therapeutic development.
Backed by global compliant QC standards and expert regulatory support, our GMP grade Cas proteins have supported seven IND approvals to date, with FDA DMF activated and ready for IND application.
| Cas9 | eSpCas9 | Cas12a/MAD7 | Cas13a | Prime Editor | Base Editor | |
|---|---|---|---|---|---|---|
 |
|
 |
 |
 |
 |
|
| Target | DNA | DNA | DNA | DNA | DNA | DNA |
| Cleavage | Doublestrand break, blunt | Doublestrand break, blunt | Doublestrand break, staggered | Singlestrand break | Single-strand break | Single-strand break |
| Suggested Application | Highly efficient KO/KI | High fidelity, low off-target editing | Multiplex editing, DNA detection | RNA cleavage and detection | Single-base substitutions, short insertion/deletions | Single-base substitutions (A->T, C->G) |
Off-the-shelf Cas proteins licensed from the Broad Institute.
Next-gen editors
First-in-market Prime and Base editors
High-fidelity
Low off-target eSpCas9 for enhanced specificity
High Purity & Quality
Over 90% purity to ensure reliability and consistency
Regulatory Track Record
7 global IND approvals supported to date
DMF on file with FDA
Cas9 Nucleases
SpCas9 (Streptococcus pyogenes Cas9) is a widely used RNA-guided endonuclease in CRISPR Cas9 genome editing, recognizing a 5'-NGG-3' PAM sequence to create blunt-ended doublestrand breaks 3 bp upstream of the PAM. Cas9 nuclease variants including high-fidelity and wild-type versions, are provided for precise, efficient genome editing across a wide range of research and therapeutic applications. Most of the Cas9 protein products are equipped with NLS to facilitate high editing efficiency in eukaryocytes, while the non-NLS Cas9 provides the efficient tool for microbial genome editing. Click on each product link to learn more.
High fidelity eSpCas9
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03622
|
GenCRISPR™ Ultra eSpCas9-2NLS-Research |
|
$765.00 |
|
Wild type SpCas9
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
RC00001
|
GenCRISPR™ NLS-wtSpCas9, his-tag |
|
$150.00 |
|
|
Z03386
|
GenCrispr Cas9 Nuclease |
|
$35.00 |
|
|
Z03621
|
GenCRISPR™ Ultra NLS-Cas9-Research |
|
$695.00 |
|
|
Z03702
|
GenCRISPR™ Cas9 v1.2 |
|
$188.00 |
|
EGFP SpCas9
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03393
|
GenCrispr NLS-Cas9-EGFP Nuclease |
|
$188.00 |
|
|
Z03467
|
GenCrispr NLS-Cas9-EGFP Nuclease |
|
$241.00 |
|
SpCas9 Nickase
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03390
|
GenCrispr NLS-Cas9-D10A Nickase |
|
$39.00 |
|
SaCas9
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03699
|
GenCRISPR™ SaCas9 2NLS Nuclease |
|
$188.00 |
|
Explore cGMP Cas9 products for seamless scale-up to clinical development
Cas12a Nucleases
Cas12a (formerly Cpf1) is a Class 2 Type V CRISPR-Cas protein used for precise genome editing and nucleic acid detection. Unlike Cas9, Cas12a recognizes T-rich PAM sequences, offering editing in regions beyond Cas9 reach. They also produce staggered cuts and enable higher editing accuracy. Cas12a can process their own guide RNA assay and thus is favored for multiplex editing. Cas12a nucleases also exhibit collateral ssDNA cleavage, enabling highly sensitive diagnostic applications on DNA samples. AsCas12a, LbCas12a and ErCas12a (MAD7) are all members of the Cas12a (Cpf1) CRISPR nuclease family with different origins and PAM preference. Click on each product link to learn more.
MAD7
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
RC00012
|
GenCRISPR™ Ultra ErCas12a-3NLS, His-tag |
|
$196.00 |
|
|
Z03762
|
GenCRISPR™ ErCas12a Nuclease |
|
$189.00 |
|
AsCas12a
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03502
|
GenCRISPR™ Cas12a (Cpf1) Nuclease |
|
$113.00 |
|
LbCas12a
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03753
|
GenCRISPR™ LbCas12a Nuclease |
|
$189.00 |
|
Cas13a Nucleases
Cas13a nucleases are Class 2 Type VI CRISPR-Cas enzyme that acts as an RNA-guided, RNAtargeting ribonuclease. Upon recognizing its target RNA, Cas13a activates a unique "collateral cleavage" mechanism, non-specifically degrading nearby RNA molecules. This collateral activity is harnessed for ultra-sensitive, programmable molecular diagnostics for RNA based diagnostics like pathogen detection. LwaCas13 and LbuCas13 are from different origins, while both exhibit high efficiency and offered at 4mg/ml, and LbuCas13 as the tag-free option. Click on each product link to learn more.
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
Z03486
|
GenCRISPR™ Cas13a (C2c2) Nuclease |
|
$189.00 |
|
|
Z03742
|
GenCRISPR™ LbuCas13a Nuclease |
|
$189.00 |
|
Prime Editors and Base Editors
Beyond nuclease-based editing, base and prime editors have emerged as nextgeneration genome engineering technologies that enable higher-precision modifications without introducing double-strand breaks (DSBs). By avoiding DSBs, these systems reduce editing-associated errors such as indels and chromosomal rearrangements, resulting in more predictable outcomes.
Base editors typically combine a catalytically impaired Cas protein, such as D10A nickase, with a deaminase to achieve targeted single-base conversions. Adenine base editors (ABEs) mediate A→G substitutions, while cytosine base editors (CBEs) enable C→T conversions. Prime editors pair a Cas nickase with a reverse transcriptase and a prime editing guide RNA (pegRNA) to install a broader range of precise edits, including substitutions, insertions, and deletions, with reduced dependence on donor templates.
Together, these features expand the versatility of genome editing and enable a wider range of therapeutic and research applications.
Base Editors
| Cat. No. | Product Name | Quantity | Price | Order |
|---|---|---|---|---|
|
RC00010
|
ABE8e |
|
$200.00 |
|
Prime Editors
With our years of expertise in Cas protein, Base editor and Prime editor production, we deliver tailored enzymes across RUO to cGMP—built to meet your exact editing goals. Backed by proprietary engineering platforms and rapid gene synthesis, we offer fast, reliable, high purity and comprehensive Cas protein production service tailored to your needs. Projects can be completed in as little as 2 weeks, with regulatory support for IND submissions. From early discovery to therapeutic development, our custom solutions accelerate your CRISPR pipeline.
95% success rate
With proprietary engineering platforms
Industrial-leading Speed
Production in as little as 2 weeks
Activity Assay Development
Established protocol developed in-house
High Purity
With dual-tag strategy
| Cas nuclease variants | Base editor/Prime editor | |
|---|---|---|
| Amount | Scalable from µg to g level | |
| Tag | Strep and His dual-tag strategy for enhanced purity | |
| QC Standard (default) |
|
|
| Timeline | 3-6 weeks | |
| Optional services and QC |
|
|
Interested in GMP grade customization service of Cas protein, Base Editor and Prime Editor? Check out our cGMP Cas Protein capability here
We offer cGMP Cas9 proteins off-the-shelf, as well as custom cGMP bacterial expression for a variety of CRISPR proteins.
High fidelity eSpCas9
The fidelity and editing efficiency of GenCRISPR eSpCas9 Protein were evaluated against wildtype Cas9 on Jurkat cells and primary T cells. GenCRISPR eSpCas9 exhibited a superior ability to reduce off-target edits.
Low off-target effects_Jurkat cells
Low off-target effects_ Primary T cells
GenCRISPR eSpCas9 exhibits comparable knockout and knock-in efficiency to the wildtype SpCas9 in both Jurkat cells and primary T cells.
High Knockout_ Jurkat cells and Primary T cell
High Knock-in_ Primary T cell
The GenCRIPSR™ Ultra eSpCas9 (mt) shows high batch-to-batch consistency, with no significant differences in cell viability and consistent knockout/knock-in efficiency across the three batches at any concentration.
KO at TRAC sites in HEK293T cells
GFP KI at RAB11A in Jurkat cells
GenCRISPR eSpCas9 exhibits lower off-target effects compared to HiFi Cas9 products from leading suppliers, while its knockout and knock-in efficiencies are equivalent to or exceed those of the leading suppliers.
Low off-target effects_HEK293 T cell
High Knockout efficiency_HEK293 T cell
High Knock-in efficiency_Primary T cell
WT SpCas9
GenCRISPR SpCas9 demonstrated high gene editing efficiency in both in vitro cleavage tests and HEK293T cells.
In vitro cleavage test
Gene knockout efficiency_HEK293 T cell
Gene knockout efficiency_293 T cells & Jurkat cells
GenCRISPR SpCas9 is used for gene knockout in 293T cells and Jurkat cells. As shown in the figure, the gene knockout efficiency of three batches shows no significant difference.
GenCRISPR SpCas9 is used for gene knockout in 293T cells and Jurkat cells. As shown in the figure, the gene knockout efficiency is equivalent to that of the leading supplier I.
MAD7
Higher editing efficiency was observed for β2M knockout in Jurkat cells using GenCRISPR™ Ultra ErCas12a-3NLS, His-tag (Cat. No. RC00012) compared to Supplier A, as assessed by NGS and flow cytometry for gene and protein knockout.
Higher knock-in efficiency with triple knockout was observed in primary human T cells using GenCRISPR™ Ultra ErCas12a-3NLS, His-tag (Cat. No. RC00012) compared to all other suppliers’ products tested.
On-time delivery of Cas12 mutant with high purity, low endotoxin, and nondetectable DNase, presenting higher activity than wild type in in-vitro cleavage assay with in-house gRNA and validated protocol.
QC report
| Concentration by Bradford | Endotoxin | Purity by SDS-PAGE | Purity by SEC-HPLC | DNase detection | Amount |
|---|---|---|---|---|---|
| 4.93mg/mL | 0.648EU/mg | 90% | 94% | No detected | ~5mg |
In vitro cleavage test
Red arrow: Full-length
dsDNA substrate
Green arrow: Fragment-1 dsDNA
Blue arrow: Fragment-2 dsDNA
Base editor
Gene editing efficiency in Jurkat cells using ABE8e RNP
High A to G conversion across different doses
ABE8e protein effectively knocks out B2M protein
Prime editor
Gene editing efficiency in HEK293T cells using PE7 RNP at 50 pmol
PE7 mediated targeted 5 bp deletions at the HEK3 locus in HEK293 cells
No significant impact on cell viability
| Type | ABE (TadA_nCas9) | CBE (APOBEC_nCas9) | PE (Cas9_RT) |
|---|---|---|---|
| Purification procedure |
|
|
|
| Purity | >90%, by SDS-PAGE under reducing conditions. | >90%, by SDS-PAGE under reducing conditions. | >90%, by SDS-PAGE under reducing conditions. |
| Yield | 1.6mg/L | 22.03mg/L | 12.3mg/L |
See what researchers worldwide have achieved with our Cas proteins:
View Citations
Jack Castelli
Fred Hutchinson Cancer Center
"The people at GenScript have been tremendously helpful in providing materials for our lab. We've been able to test novel CRISPR systems such as prime editing and PASSIGE in a timely manner thanks to their work. I would recommend their services for your editing needs."
MariaMorello Miravet
Karolinska Institutet
"We are very pleased with the editing efficiency using base editors from GenScript, we got up to 100% KO!"
CRISPR/Cas Nuclease Solutions
From Discovery to GMP – The Complete Toolkit for Next-Generation Gene Editing
Free Download
Catalog mRNA, saRNA, ciriRNA, LNPs and ladders
Ready To Use RNA and LNPs– Empowering Discovery and Innovation
Free Download
CRISPR RNP Handbook
Enabling RNP-mediated CRISPR gene editing and transforming life science research
Free Download
GenCRISPR™ Gene Editing Solutions
All solutions you need for a successful CRISPR gene editing project
Free Download
Protocol: Prime Editing in HEK 293T cells with RNP
Material, method, troubleshooting guidance, and case studies
Free Download
Unlocking CRISPR: Advances in Base Editing & Prime Editing and Future Applications
Dr. Jiabao Lv, Sr. Protein Scientist
Watch NowGenScript offers a broad catalog of ready-to-use Cas nucleases in protein format, including Cas9, Cas12a, Cas13a, MAD7, Base Editors, and Prime Editors. These are available in both RUO (Research Use Only) and GMP-grade formats to support applications from early discovery to clinical manufacturing.
Yes. Our custom Cas protein service can engineer and produce nucleases precisely to your specifications—covering RUO through cGMP production. We deliver defined yield, purity, and activity, with guaranteed performance packages and production timelines as short as two weeks.
Our catalog products are ideal for widely used gene editing applications where validated, off-the-shelf options meet your needs.
Custom Cas proteins are recommended if you require unique formats, novel nucleases, enhanced fidelity, altered PAM specificities, or other custom specifications.
All Cas proteins undergo rigorous QC testing for purity, activity, and minimal off-target effects. GMP-grade nucleases are manufactured following current Good Manufacturing Practice (cGMP) guidelines and are compliant with FDA/EMA/PMDA/NMPA regulations.
Catalog products are available with rapid turnaround and global shipping. Custom Cas protein projects can be completed in as little as two weeks after sequence confirmation, depending on complexity and production scale.
Yes. We offer GMP-grade enzymes specifically designed to meet the high performance, traceability, and compliance requirements of therapeutic development—from preclinical through commercial production.
The catalog nucleases in our portfolio are licensed from the Broad Institute, providing access to validated products with streamlined IP pathways. For custom projects, our team can work with you to address licensing and regulatory considerations to minimize delays in your program.
Our scientists provide technical support, troubleshooting, and regulatory guidance, including data packages to support IND filing. We work as an extension of your team from concept to scale-up.
Our Cas nucleases are validated for a range of applications, including:
You can browse our catalog Cas proteins online for immediate online ordering, or contact our custom services team to discuss your specifications, timelines, and regulatory requirements.
